A phase I study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor targeted therapies

PURPOSE: The PI3K/Akt/mTOR pathway is dysregulated in metastatic renal cell carcinoma (mRCC). Buparlisib is a pan-PI3K inhibitor with activity in advanced solid tumors. The primary aim of this study was to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of buparlisib a...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer
Asıl Yazarlar: McKay, Rana R., De Velasco, Guillermo, Werner, Lillian, Bellmunt, Joaquim, Harshman, Lauren, Sweeney, Christopher, Rosenberg, Jonathan E., Hirsch, Michelle, Signoretti, Sabina, Van Allen, Eliezer, Walsh, Meghara, Vaishampayan, Ulka, McDermott, David F., Choueiri, Toni K.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2016
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5567751/
https://ncbi.nlm.nih.gov/pubmed/27198170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30056
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller